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Background: This study was designed to compare the efficacy and safety of thymosin-_1 (T-_1) with that of interferon-
_ (IFN-_) in patients with chronic hepatitis B who were positive for hepatitis B virus (HBV) DNA and hepatitis B
envelope antibody (anti-HBe).
Methods: Fifty-six patients were randomly divided into groups A and B. Both groups were comparable (p > 0.05)
at baseline regarding age, sex, and alanine aminotransferase (ALT) levels. Group A patients received T-_1 1.6 mg
subcutaneously twice weekly, while group B patients received IFN-_ 5 million IU daily for 15 days, then thrice weekly
for 6 months. Results from the 2 groups were compared with data from a group of 30 patients never treated with
IFN-_ and who were followed-up for 12 months (historical control [HC] group); the 3 groups were comparable
(p > 0.05).
Results: After treatment, a complete response (ALT normalization and HBV DNA loss) occurred in 8 of 26 patients
in group A (30.8%) and 14 of 30 in group B (46.7%; r2 = 1.476, p = 0.224). After a follow-up period of 6 months,
a complete response was observed in 11 of 26 patients in group A (42.3%) and 7 of 30 in group B (23.3%;
r2 = 2.299, p = 0.129). The rate of complete response was significantly greater in the IFN-_ than HC group at
the end of therapy (46.7% vs 3.3%; r2 = 15.022, p = 0.0001), and in the T-_1 than HC group at the end of follow-
up (42.3% vs 3.3%; r2 = 12.566, p = 0.0001). Ten of the 12 T-_1 responders (i.e. partial responders; 83.3%)
experienced sustained, non-detectable HBV DNA after 6 months’ treatment; 6 of the 14 T-_1 non-responders
(42.9%) showed a delayed response of non-detectable HBV DNA during the follow-up period. Corresponding values
for group B patients were 50% (9/18) and 0% (0/12). The rate of delayed response was significantly higher in
group A than the other 2 groups (r2 = 6.686, p = 0.010; r2 = 4.964, p = 0.038), whereas the rate of flare was
higher in group B than in the other 2 groups (r2 = 3.445, p = 0.063; r2 = 7.668, p = 0.006), during the follow-
up period. Unlike IFN-_, T-_1 was well tolerated, i.e. no adverse effects were noted in group A.
Conclusion: These results suggest that a 6-month course of T-_1 therapy is effective and safe in patients with
anti-HBe-positive chronic hepatitis B; T-_1 can reduce HBV replication in such patients. Compared with IFN-_,
T-_1 is better tolerated and seems to induce a gradual and more sustained normalization of ALT and loss of HBV
DNA. Combination therapy with T-_1 and IFN-_ or nucleoside analogs for hepatitis B warrants further study. [J Chin
Med Assoc 2005;68(2):65–72]
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Introduction
Chronic viral hepatitis is the principal cause of chronic
liver disease, cirrhosis, and hepatocellular carcinoma
(HCC) worldwide and now ranks as the chief reason
for liver transplantation in adults.1–4 The World Health
Organization estimates that hepatitis B virus (HBV)
has infected more than 350 million people worldwide,
and up to 20% of those infected will go on to become
chronic carriers and be at significant risk of cirrhosis
and HCC. The ultimate goals of therapy for chronic
hepatitis B are to prevent progression to cirrhosis and
the development of HCC. Various subgroups of
hepatitis B surface antigen (HBsAg)-positive patients
with chronic hepatitis have been identified. Typical
HBsAg-positive patients have hepatitis B envelope
antigen (HBeAg) and HBV DNA in serum during the
active phase of the disease, and usually show disease
remission if they seroconvert to HBeAg antibody
(anti-HBe). However, a subset of HBsAg-positive
patients lacks HBeAg, but instead has anti-HBe and
HBV DNA present in serum. The latter form of hepa-
titis is characterized by a progressive and relapsing
disease course with fluctuations in viral replication5,6
and a poor response to interferon-alpha (IFN-_).7–18
The treatment of chronic hepatitis B is directed
towards inhibition of viral replication, followed by
elimination of the virus. Histologic improvement of
hepatic inflammation and normalization of amino-
transferase levels are additional treatment goals. At
present, the only treatment of proven benefit in chronic
viral hepatitis is IFN-_. In chronic hepatitis B, a 4–
6-month course of IFN-_ is effective in inducing
clearance of HBV DNA and HBeAg from serum, and
in improving serum aminotransferase levels and liver
histology in 25–40% of patients.17 Chronic HBV
infection is believed to result, in part, from an inade-
quate host immune response to the virus.19,20 Thus,
immunomodulatory drugs, including thymic humoral
factor-a2 (THF-a2) and thymosin-_1 (T-_1) have
been tested in clinical trials both as monotherapy and
in combination with IFN-_.21–30
T-_1 is an immune modifier (a 28-amino acid
peptide) that triggers maturational events in
lymphocytes, augments immunoregulatory T-cell
function, and promotes reconstitution of immune
defects.31,32 While not completely understood, the
mechanism of T-_1 action is thought to be immune
system modulation through augmentation of T-cell
function.33 In vitro studies resulted in T-cell differenti-
ation and maturation, with increases in CD4+, CD8+
and CD3+ cell counts, interferon-a, interleukin (IL)-
2, and IL-3. Antigen-stimulated expression of IL-2
receptors was also observed. Immunosuppressed
animals given T-_1 experienced a cytoprotective effect
that led to increased survival time and numbers. T-_1
promotes disease remission and cessation of HBV
replication in patients with HBeAg-positive chronic
hepatitis B, and without significant adverse effects.21–30
Moreover, clinical trials of T-_1 in patients with
immunodeficiency or cancer indicate that this agent is
nontoxic, enhances immune responsiveness, and
augments specific lymphocyte functions, including
lymphoproliferative responses to mitogens, maturation
of T-cells, antibody production, and T-cell-mediated
cytotoxicity.34,35 Based on these observations, we
conducted a randomized, controlled trial to compare
the efficacy and safety of T-_1 with that of IFN-_ in




Fifty-six Chinese patients were enrolled in the study.
All patients met the following criteria: age over 18 but
less than 60 years; the presence of HBsAg in serum for
at least 1 year; the presence of serum anti-HBe and
HBV DNA documented on at least 2 occasions, at
least 3 months apart, within a period of 12 months
before randomization; elevated serum alanine
aminotransferase (ALT) on at least 2 occasions, at
least 3 months apart, with a value of * 1.5 times the
upper limit of normal for at least 12 months; and liver
biopsy features consistent with chronic hepatitis. Liver
biopsy must have been performed in the year before
screening. Eligible patients with evidence of cirrhosis
were also included. Additional requirements were a
hemoglobin value of * 100 g/L; a platelet count of
* 60,000/mm3; a white cell count of * 3,000/mm3; a
polymorphonuclear leukocyte count of * 1,500/mm3;
and normal renal function, with normal serum
creatinine levels. Candidates were required to have
compensated liver disease and no history of hepatic
encephalopathy or ascites, or esophageal or gastric
varices at risk of bleeding. Principal patient charac-
teristics at study enrollment are shown in Table 1. The
following patients were excluded: those treated with
immunosuppressive or antiviral therapy in the year
before entry; those with concurrent hepatitis C virus,
hepatitis b virus, or human immunodeficiency virus
infection; those with causes of liver disease other than
HBV; intravenous drug abusers; pregnant women;
women unwilling to practice contraception during the
study; and patients with malignancy, decompensated
Thymosin alpha-1 versus interferon-alpha in chronic hepatitis B
67J Chin Med Assoc • February 2005 • Vol 68 • No 2
liver disease, chronic renal failure, or other serious
medical illnesses or psychiatric problems that might
interfere with the trial.
Thirty patients with the same virologic and clinical
characteristics, and who had never been treated with
IFN-_, were followed-up for * 12 months and served
as a historical control (HC) group.
Study protocol
The 56 patients were randomly divided into 2
groups to receive a 6-month course of either T-_1
(Zadaxin®, supplied by SciClone Pharmaceuticals Inc,
San Mateo, CA, USA) 1.6 mg subcutaneously twice
weekly (n = 26), or IFN-_ (SINOGEN®, supplied by
Shenzhen Kexing Biotech Co Ltd, Shenzhen, China)
5 million IU subcutaneously daily for 15 days and then
thrice weekly (n = 30); patients in the HC group were
followed-up without specific treatment. All patients
were assessed every 2 weeks for the first 2 months, and
then monthly, for a total study duration of 12 months.
After the initial study period, patients were enrolled
for long-term follow-up, during which they were seen
at irregular intervals.
At each visit, patients were examined, and blood
samples were taken for biochemical and hematologic
analyses, and for HBV markers. Clinical and laboratory
assessments comprised a detailed history, including
post-injection symptoms, physical examination, rou-
tine serum biochemical tests (serum ALT, aspartate
aminotransferase [AST], r-glutamine transpeptidase
[r-GT], alkaline phosphatase [AKP], albumin, globu-
lin, bilirubin), complete cell count, markers of HBV
replication, and urinalysis. All biochemical and hema-
tologic tests were performed with routine automated
techniques. HBV markers (HBsAg, anti-HBsAg
antibody, HBeAg, anti-HBe antibody, anti-hepatitis
B core [HBc] antibody, and logarithm of anti-HBc
antibody) were detected by enzyme-linked immuno-
sorbent assay (ELISA) methods. Serum HBV DNA
levels were measured by polymerase chain reaction
(PCR) assay: this assay has a sensitivity of 5.0 = 102
copies/mL, and its linear quantification ranges between
5.0 = 103 and 5.0 = 107 copies/mL.
At a long-term follow-up visit, blood samples were
taken for analysis of HBV DNA and ALT levels.
Patients were monitored for compliance with the
study protocol by injection-vial counts, telephone
communication, and attendance at scheduled out-
patient appointments.
Clinical responses
Clinical responses were evaluated, both at the end of
treatment and follow-up. A virologic response was
defined as sustained disappearance of serum HBV
DNA, and a biochemical response as sustained
normalization of serum ALT (on at least 2 consec-
utive occasions, at least 3 months apart). At the end of
treatment and follow-up, a complete response (CR)
was defined as sustained serum HBV DNA-negative
status, and normalization of ALT activity. A delayed
response (DR) was defined as non-detectable HBV
DNA during the follow-up period. Relapse was as-
sessed on the basis of ALT flare and/or HBV DNA
reappearance during follow-up.
Table 1. Patient characteristics at study entry*
T-_1 group IFN-_ group HC group
(n = 26) (n = 30) (n = 30)
Male:female (n) 23:3 23:7 22:8
Age (yr)† 47 (  12 40 (  11 45 (  13
Duration of infection (yr)† 9.0 ( 4.8 8.7 ( 4.2 9.5 ( 5.3
Cirrhosis at entry (n) 3 3 5
Previous IFN-_ therapy (n) 0 0 0
Serum ALT (U/L)†§ 188.7 ( 102.6 191.5 ( 106.5 186.9 ( 117.4
Serum AST (U/L)†§ 144.5 ( 86.51 158.6 ( 81.81 146.2 ( 73.31
Albumin (g/L)†§ 46 (  81 46 (  71 47 (  41
Total bilirubin (+mol/L)†§ 18.4 ( 9.31 15.9 ( 8.61 16.3 ( 8.41
Serum HBV DNA‡
   < 5.0 = 105 copies/mL 17 (27) 12 (40) 11 (37)
   * 5.0 = 105 copies/mL 19 (73) 18 (60) 19 (63)
*No significant differences were observed between groups; †data are expressed as mean ( standard deviation; ‡data are expressed as number
(%); §normal values: ALT < 40 IU/L; AST < 40 IU/L; albumin 35–55 g/L; total bilirubin < 17 +mol/L.
ALT = alanine aminotransferase; AST = aspartate aminotransferase; HBV = hepatitis B virus; HC = historical control; IFN-_ = interferon-_; T-
_1 = thymosin-_1.
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Statistical analysis
A Chi-squared test was used to analyze data, with a p
value of less than 0.05 considered statistically significant.
Results
No patients withdrew from the study, and all completed
the 6-month follow-up period. At study entry, the
3 groups were not significantly different regarding
age, sex, biochemical, histologic and serologic
parameters, and the number of patients with histologic
evidence of cirrhosis (Table 1).
Biochemical and virologic changes at the end of
treatment and follow-up are shown in Table 2. In the
group receiving T-_1, serum HBV DNA was negative
in 12 of 26 patients (46.2%) at the end of treatment.
During follow-up, 6 other patients showed HBV
DNA loss (at the second [n = 1], third [n = 1], fifth
[n = 2] and sixth months [n = 2]), whereas HBV DNA
reappeared in 2 patients (at the second [n = 1] and
third months [n = 1]). In the group receiving IFN-_,
18 of 30 patients (60%) showed HBV DNA loss at the
end of treatment. However, during 6 months’ follow-
up, HBV DNA reappeared in 9 patients (at the first
[n = 2], second [n = 5] and third months [n = 2]),
while no one lost HBV DNA. In the HC group, HBV
DNA became negative in 3 of 30 patients (10%; at the
sixth [n = 2] and twelfth months [n = 1]), whereas
HBV DNA reappeared in 1 patient (at the eighth
month).
The numbers of patients with a CR, DR or flare
are shown in Table 3. Ten of the 12 T-_1 responders
(83.3%) experienced sustained non-detectable HBV
DNA after the 6-month treatment period. Six of the
14 T-_1 non-responders (42.9%) showed a DR of
non-detectable HBV DNA during the follow-up
period; corresponding values for the IFN-_ group
were 50% (9/18) and 0% (0/12). The DR rate was
significantly greater in the T-_1 group than in the
other two groups (r2 = 6.686, p = 0.010; r2 = 4.964,
p = 0.038), and the rate of flare was higher in the
IFN-_ group than in the other 2 groups (r2 = 3.445,
p = 0.063; r2 = 7.668, p = 0.006), during the follow-
up period. A significantly greater proportion of pa-
tients in the T-_1 and IFN-_ groups than the HC
group had HBV DNA loss at the end of therapy (r2 =
11.58 [p = 0.001] and r2 = 19.20 [p = 0.0001], respec-
tively) and follow-up period (r2 = 19.23 [p = 0.0001]
and r2 = 5.46 [p = 0.020], respectively).
Serum ALT levels were normalized in 10 of 26
patients in the T-_1 group (38.5%), and in 15 of 30
patients in the IFN-_ group (50.0%), at the end of
treatment, and in 3 of 30 patients in the HC group
(10.0%) after 6 months’ follow-up. During follow-up,
8 patients receiving T-_1 had ALT levels normal-
ized and 1 patient had ALT flare, whereas no patients
receiving IFN-_ had ALT levels normalized and
5 patients had ALT flare. In the HC group, 2 patients
had ALT levels normalized between the sixth and
twelfth months of follow-up; ALT flare occurred in
the 3 patients with ALT normalization during the
first 6 months of follow-up. At study completion, a
Table 2. Responses to treatment [number (%) of patients] in patients with chronic hepatitis B
T-_1 group IFN-_ group HC group
(n = 26) (n = 30) (n = 30)
After 6 months’ treatment After 6 months’ follow-up
ALT normalization  10 (38.5)* 15 (50)† † † 3 (10).
HBV DNA negative 12 (46.2)† 18 (60)‡ 1 2 (6.7)
ALT normalization and HBV DNA negative 18 (30.8)† 14 (46.7)‡s 1 (3.3)
After 6 months’ follow-up After 12 months’ follow-up
ALT normalization  17 (65.4)‡§ 10 (33.3)†s 2 (6.7)
HBV DNA negative  16 (61.5)‡§ 19 (30.0)* 2 (6.7)
ALT normalization and HBV DNA negative  11 (42.3)‡§ 17 (23.3)* 1 (3.3)
*p < 0.05 vs HC; †p < 0.01 vs HC; ‡p = 0.0001 vs HC; §p < 0.05 vs IFN-_.
ALT = alanine aminotransferase; HBV = hepatitis B virus; HC = historical control; IFN-_ = interferon-_; T-_1 = thymosin-_1.
Table 3. Responses [number (%) of patients] to treatment
at the end of the study
CR DR FN
T-_1 11 (42.3)* 1 6 (23.1)†  2 (7.7)‡
IFN-_  7 (23.3)† 0 (3.3) 9 (30)§
HC 1 (3.3)1 1 (3.3) 1 (3.3)
*p = 0.0001 vs HC; †p < 0.05 vs HC; ‡p < 0.05 vs IFN-_; §p < 0.01 vs
HC. CR = complete response; DR = delayed response; FN = flare number;
HC = historical control; IFN-_ = interferon-_; T-_1 = thymosin-_1.
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CR was observed in 11 of 26 patients treated with
T-_1 (42.3%), in 7 of 30 receiving IFN-_ (23.3%), and
in 1 of 30 in the HC group (3.3%) (T-_1 vs IFN-_:
r2 = 2.30, p = 0.129; and T-_1 vs HC: r2 = 12.57,
p = 0.0001).
The typical adverse effects of IFN-_ therapy, such
as flu-like syndrome, fatigue, irritability, and headache,
were seen in most IFN-_ recipients; however, no
serious or long-term adverse effects were noted, and
no patients discontinued treatment. Treatment with
T-_1 was not associated with significant adverse ef-
fects: only 1 patient reported local discomfort at injec-
tion sites; no systemic or constitutional symptoms were
observed; and no dosage adjustment was required.
Discussion
Anti-HBe-positive patients respond less often to
IFN-_ therapy than do HBeAg-positive patients and
often relapse when treatment is stopped.7–18,36–39 Clinical
studies suggest that IFN-_ 3–9 million IU thrice
weekly for 6 months can suppress HBV replication
in more than 50% of treated patients, but the relapse
rate after treatment withdrawal is high.7–18 In our
study, a CR was seen in 46.7% of patients at the end of
treatment, and in 23.3% at the end of follow-up.
New therapies are needed for hepatitis B, especially
for HBeAg-negative hepatitis B, because the overall
rate of beneficial response to IFN-_ is not satisfactory
and re-treatment is rarely helpful.17 Agents evaluated
for use against hepatitis B include prednisone,
interferon-a, thymosin, vaccination with antigenic HBV
epitope, adoptive transfer of immunity, and several
new nucleoside analogs, such as lamivudine,
famciclovir, lobucavir, and adefovir dipivoxil.17 Trials
of long-term therapy, and of combination therapy
with IFN-_, are now under way.
The present randomized, controlled trial shows
that T-_1 1.6 mg subcutaneously twice weekly for
6 months is effective and safe in anti-HBe-positive
and HBV DNA-positive chronic hepatitis B, because
42.3% of treated patients became HBV DNA-negative
6 months after the end of treatment. This response
rate is not only significantly higher than the spontane-
ous seroconversion rate (3.3% in this study), but
also higher than the response to IFN-_ therapy alone
(23.3%), assessed 6 months after the end of therapy.
No significant differences were identified between
the T-_1 and IFN-_ groups at the end of treatment
regarding rates of ALT normalization (r2 = 0.75; p =
0.386) or HBV DNA loss (r2 = 1.07; p = 0.3). How-
ever, significant differences were evident between
the 2 groups regarding response rates at the end of
follow-up (r2 = 5.73, p = 0.017 and r2 = 5.61, p =
0.018, respectively). The rate of CR was not signifi-
cantly different between the 2 groups at the end of
treatment (r2 = 1.48; p = 0.224) and follow-up (r2 =
2.30; p = 0.129). Normalization of serum ALT and
loss of HBV DNA were observed more frequently in
the IFN-_ group at the end of therapy and in the
T-_1 group at the end of follow-up. Furthermore, in
the T-_1 but not the IFN-_ group, an additional
response to treatment was also observed during the
follow-up period.
Based on these results, and considering that ALT
normalization and HBV DNA loss may occur spon-
taneously in untreated patients infected by pre-core
mutant virus, we retrospectively compared the 2
treated groups with a group of untreated patients
followed-up for at least 12 months. The results showed
a significantly greater CR rate in the IFN-_ group at
the end of treatment, and in the T-_1 group at the end
of follow-up, compared with the HC group. The
outcome of this study contrasts with other clinical
trials in patients with chronic hepatitis B, where T-_1
was shown to be both effective and safe when used as
monotherapy or in combination with IFN.21–23,25,27–30
It was reported in a multicenter, American trial that
5 of 12 responders to T-_1 therapy had a DR.29 This
is in contrast to IFN-_, to which responses usually
occur during the first 4 months of treatment. These
contrasting patterns of response were best demon-
strated in a recent Italian study involving HBeAg-
negative, HBV DNA-positive, interferon-naive patients
with high ALT levels (181 ( 159 U/L), in which the
CR rate increased gradually from 29.4% at the end of
T-_1 treatment to 41.2% 6 months later. In that study,
the response to IFN-_ decreased from 43.8% at the
end of treatment to 25% 6 months later.30 This trend
towards a delayed effect for T-_1 in patients with
chronic hepatitis B was also recently reported by other
investigators.21–23,25,28
The characteristic delayed response to T-_1 noted
in other trials21–23,25,28–30 was also seen in the present
study. Ten of the 12 T-_1 responders (83.3%) in the
current study experienced sustained non-detectable
HBV DNA after 6 months’ treatment. Six of the 14
T-_1 non-responders (42.9%) showed a DR of non-
detectable HBV DNA during follow-up. T-_1 dosage,
injection schedules and duration of treatment in the
present study were similar to those used in other
clinical trials.21–23,25,28–30 Furthermore, the efficacy of
T-_1 in hepatitis B was recently evaluated in 353
patients in a meta-analysis of 5 trials.23 The results
showed that there was an increasing trend towards
J. You, et al
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virologic response with time since the cessation of
thymosin treatment (p = 0.02). Thymosin effectively
suppresses viral replication in chronic HBV infection,
and has a cumulative effect after treatment cessation
on viral clearance. Indeed, in the meta-analysis, as long
as 12 months were required after treatment cessation
for antiviral efficacy to become apparent. It is likely
that the results reflected the response of HBeAg-
positive patients, as such patients were studied in 4
of the 5 trials included (3 trials included HBeAg-
positive patients and 1 included both HBeAg-positive
and HBeAg-negative patients). Only 2 trials included
HBeAg-negative patients (1 trial included HBeAg-
negative patients and 1 included both HBeAg-
positive and HBeAg-negative patients).23 Thus,
whether the efficacy of thymosin in HBeAg-negative
patients differs from that in HBeAg-positive patients
requires further research, and reasons for the above-
mentioned, delayed effect of T-_1 are not yet clear.
Patients treated with T-_1 have an increased
peripheral blood helper T-cell count (CD4), and IFN-
r production by peripheral blood mononuclear cells,
during and after the end of treatment.27 T-_1 has been
used to treat patients with cancer or immunodeficiency,
resulting in up-regulation of lymphocyte function to
include mitogen responsiveness, T-cell maturation,
enhanced T-lymphocyte cytotoxicity, and increased
B-lymphocyte antibody production.32,40 Furthermore,
T-_1 is found in, and secreted by, lymphocytes, justifi-
ably characterizing it as a cytokine.41 Other thymus-
derived compounds have been used in clinical trials.
A synthetic octapeptide, THF-a2, was studied in
9 patients who had previously failed IFN-_2b
treatment,26 and appeared to potentiate the suppressive
effect of IFN-_2b on HBV replication. In view of the
immune mechanisms involved in the pathogenesis of
liver injuries in chronic HBV infection, it is possible
that T-_1 may activate viral-specific helper T-cells and
amplify the humoral immune response to viral proteins,
and the induction of viral antigen-specific cytotoxic
T-lymphocytes, by secreting endogenous IFN-_, IFN-
a, IL-2, and tumor necrosis factor; it may also increase
lymphocyte IL-2 receptor expression.42–51 Moreover,
T-_1 can act synergistically with endogenous IFN-_
and IFN-`to stimulate natural killer activity.52
Although T-_1 is not known to possess antiviral
properties, a preliminary report showed that it inhibited
woodchuck hepatitis virus replication.53 Hence, the
delayed effect after T-_1 therapy in the present study
was possibly due to immunomodulation and the
induction of persistently higher levels of helper T-cell
function. Because noncytolytic inhibition of HBV
RNA, nucleocapsid particles, and replicative DNA
intermediates by cytotoxic T lymphocytes have been
described in the transgenic mouse model,54,55 it is also
possible that viral clearance after T-_1 therapy, parti-
cularly that without a preceding ALT flare, may also be
mediated by the noncytolytic antiviral effects of cyto-
toxic T lymphocytes. Clearly, further studies are needed
to elucidate the possible mechanisms of such viral
clearance.
In conclusion, results from this trial indicate that,
at the dosage tested, T-_1 is of potential interest in
patients with anti-HBe-positive and HBV DNA-
positive chronic hepatitis B. However, a response rate
of 42.3% is still less than ideal. A potentially more
effective therapeutic approach, such as combination
therapy using the immunomodulating effect of T-_1
and the antiviral activity of interferon or nucleoside
analogs (e.g. lamivudine, famciclovir), warrants further
study.
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